# Phase II Study of Clofarabine in Adult Patients With Refractory or Relapsed Acute Myelogenous Leukemia

> **NCT00044889** · PHASE2 · COMPLETED · sponsor: **Genzyme, a Sanofi Company** · enrollment: 40 (—)

## Conditions studied

- Acute Myelogenous Leukemia

## Interventions

- **DRUG:** clofarabine (IV formulation)

## Key facts

- **NCT ID:** NCT00044889
- **Lead sponsor:** Genzyme, a Sanofi Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-05
- **Primary completion:** —
- **Final completion:** 2003-03
- **Target enrollment:** 40 (—)
- **Last updated:** 2014-03-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00044889

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00044889, "Phase II Study of Clofarabine in Adult Patients With Refractory or Relapsed Acute Myelogenous Leukemia". Retrieved via AI Analytics 2026-06-21 from https://api.ai-analytics.org/clinical/NCT00044889. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*